Trial Profile
A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Brain metastases; Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 9LA
- Sponsors Bristol-Myers Squibb
- 12 Jan 2024 Last checked against ClinicalTrials.gov record.
- 06 Sep 2023 Planned End Date changed from 3 Jan 2024 to 19 Jan 2026.
- 06 Jul 2023 Planned End Date changed from 19 Jan 2023 to 3 Jan 2024.